AstraZeneca plc (AZN) Given Buy Rating at Berenberg Bank

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by research analysts at Berenberg Bank in a research report issued to clients and investors on Monday. They currently have a GBX 5,500 ($71.03) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price target would suggest a potential upside of 14.82% from the stock’s previous close.

AZN has been the subject of several other research reports. Liberum Capital restated a “buy” rating and issued a GBX 4,800 ($61.99) target price on shares of AstraZeneca plc in a report on Tuesday, September 5th. Morgan Stanley restated an “overweight” rating and issued a GBX 5,600 ($72.32) target price on shares of AstraZeneca plc in a report on Friday, June 23rd. UBS AG set a GBX 4,550 ($58.76) target price on shares of AstraZeneca plc and gave the company a “neutral” rating in a report on Thursday, August 31st. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a report on Monday, May 22nd. Finally, Barclays PLC restated an “overweight” rating and issued a GBX 6,000 ($77.49) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. AstraZeneca plc presently has a consensus rating of “Hold” and an average price target of GBX 4,963.82 ($64.11).

AstraZeneca plc (LON:AZN) opened at 4871.50 on Monday. The firm has a 50 day moving average of GBX 4,593.39 and a 200-day moving average of GBX 4,871.66. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s market cap is GBX 61.67 billion.

AstraZeneca plc (LON:AZN) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $1.01. AstraZeneca plc had a net margin of 8.83% and a return on equity of 14.36%. On average, analysts expect that AstraZeneca plc will post $3.75 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “AstraZeneca plc (AZN) Given Buy Rating at Berenberg Bank” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://sportsperspectives.com/2017/09/11/astrazeneca-plc-azn-given-buy-rating-at-berenberg-bank.html.

In related news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply